Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie

Astrazeneca überzeugt mit Daten zu Brustkrebsmittel

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat positive Daten zu einem Medikamentenkandidaten zur Behandlung von Brustkrebs vorgelegt. Der Wirkstoff…

3 Magnificent Growth Stocks to Buy Right Now

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks…

AstraZeneca receives A1 rating upgrade from Moodys, outlook stable By Investing.com

AstraZeneca receives A1 rating upgrade from Moodys, outlook stable…

AstraZeneca Rises Almost 9% in a Month: How to Play the Stock

AZNs key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.…

FTSE 100 dips as heavyweight ex-dividends drag, Lloyds soars

The FTSE 100 dropped again on Thursday as companies accounting for a significant proportion of the index traded ex-dividend and…

4 AI Stocks to Watch in the Quantum Computing Revolution

Following the stock markets record-breaking 2024, during which the S&P 500 index returned a spectacular 23%, theres optimism among investors…

Directorate Change

18 February 2025 Non-Executive Board Changes AstraZeneca PLC announced today that Karen Knudsen will be proposed for election as a Non-Executive Director…

AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally…

AZN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Feb. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the worlds leading drugmakers, missed last years strong market rally.…

dpa-AFX ProFeed